WO2008033351A3 - Multimodal abuse resistant and extended release formulations - Google Patents
Multimodal abuse resistant and extended release formulations Download PDFInfo
- Publication number
- WO2008033351A3 WO2008033351A3 PCT/US2007/019745 US2007019745W WO2008033351A3 WO 2008033351 A3 WO2008033351 A3 WO 2008033351A3 US 2007019745 W US2007019745 W US 2007019745W WO 2008033351 A3 WO2008033351 A3 WO 2008033351A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- extended release
- multimodal
- abuse resistant
- release formulations
- abuse
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/485—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
Abstract
The present invention is in the field of oral, abuse resistant pharmaceutical compositions of abusable drugs, extended release pharmaceutical compositions of abusable drugs and extended release abuse resistant pharmaceutical compositions of abusable drugs and the use thereof. The present invention is also directed to extended release pharmaceutical compositions and the use thereof for preventing or minimizing the risk of abuse and/or toxicity from either intentional or unintentional tampering. The present invention is further directed at a method of preventing or minimizing the risk of abuse and/or toxicity from either intentional or unintentional tampering.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US84339206P | 2006-09-11 | 2006-09-11 | |
US60/843,392 | 2006-09-11 | ||
US90798707P | 2007-04-26 | 2007-04-26 | |
US60/907,987 | 2007-04-26 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2008033351A2 WO2008033351A2 (en) | 2008-03-20 |
WO2008033351A3 true WO2008033351A3 (en) | 2009-04-09 |
Family
ID=39184298
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2007/019745 WO2008033351A2 (en) | 2006-09-11 | 2007-09-12 | Multimodal abuse resistant and extended release formulations |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2008033351A2 (en) |
Families Citing this family (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008134071A1 (en) | 2007-04-26 | 2008-11-06 | Theraquest Biosciences, Inc. | Multimodal abuse resistant extended release formulations |
US8329744B2 (en) | 2005-11-02 | 2012-12-11 | Relmada Therapeutics, Inc. | Methods of preventing the serotonin syndrome and compositions for use thereof |
CA2655682A1 (en) | 2006-08-03 | 2008-02-07 | Nitec Pharma Ag | Delayed-release glucocorticoid treatment of rheumatoid disease |
MX2008010233A (en) * | 2008-03-10 | 2009-11-10 | Eurodrug Lab B V | Modified release composition comprising doxofylline. |
JP5594484B2 (en) * | 2009-07-06 | 2014-09-24 | 杏林製薬株式会社 | Tablet with hollow structure |
AT509000B1 (en) * | 2009-10-23 | 2012-12-15 | Rausch Peter | WATER-SOLUBLE PREPARATIONS OF CANNABINOIDS AND CANNABIC PREPARATIONS AND THEIR APPLICATIONS |
US9125867B2 (en) | 2010-02-24 | 2015-09-08 | Invincible Biotechnology | Diversion- and/or abuse-resistant compositions and methods for making the same |
FR2962331B1 (en) * | 2010-07-06 | 2020-04-24 | Ethypharm | PHARMACEUTICAL FORM FOR COMBATING CHEMICAL SUBMISSION, METHOD USING THE SAME |
FR2962550B1 (en) * | 2010-07-06 | 2013-06-14 | Ethypharm Sa | METHOD FOR CONTROLLING CHEMICAL SUBMISSION, USE OF COLORING AGENT FOR COMBATING CHEMICAL SUBMISSION AND PHARMACEUTICAL COMPOSITION FOR THE IMPLEMENTATION OF THE METHOD |
CA3081195C (en) | 2013-02-08 | 2022-06-21 | General Mills, Inc. | Reduced sodium food products |
CA3042642A1 (en) | 2013-08-12 | 2015-02-19 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded immediate release abuse deterrent pill |
US9492444B2 (en) | 2013-12-17 | 2016-11-15 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded extended release abuse deterrent pill |
US10172797B2 (en) | 2013-12-17 | 2019-01-08 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded extended release abuse deterrent pill |
EP3169315B1 (en) | 2014-07-17 | 2020-06-24 | Pharmaceutical Manufacturing Research Services, Inc. | Immediate release abuse deterrent liquid fill dosage form |
AU2015336065A1 (en) | 2014-10-20 | 2017-05-04 | Pharmaceutical Manufacturing Research Services, Inc. | Extended release abuse deterrent liquid fill dosage form |
WO2017096049A1 (en) | 2015-12-03 | 2017-06-08 | The University Of North Carolina At Pembroke | Materials for cathepsin b enhancement and methods of use |
US11504347B1 (en) | 2016-07-22 | 2022-11-22 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
US11602513B1 (en) | 2016-07-22 | 2023-03-14 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
UY37341A (en) | 2016-07-22 | 2017-11-30 | Flamel Ireland Ltd | FORMULATIONS OF GAMMA-MODIFIED RELEASE HYDROXIBUTIRATE WITH IMPROVED PHARMACOCINETICS |
US11602512B1 (en) | 2016-07-22 | 2023-03-14 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
CA3127871A1 (en) | 2019-03-01 | 2020-09-10 | Flamel Ireland Limited | Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state |
WO2021151169A1 (en) * | 2020-01-31 | 2021-08-05 | AusCann Group Holdings Ltd | Cannabinoid composition and manufacturing method |
WO2021151168A1 (en) * | 2020-01-31 | 2021-08-05 | AusCann Group Holdings Ltd | Method of cannabinoid therapy |
CN116261451A (en) | 2020-07-24 | 2023-06-13 | 凯瑞康宁生物工程有限公司 | Pharmaceutical compositions and pharmacokinetics of gamma-hydroxybutyric acid derivatives |
US11395801B2 (en) | 2020-10-05 | 2022-07-26 | XWPharma Ltd. | Modified release compositions of a gamma-hydroxybutyric acid derivative |
US11510892B2 (en) | 2021-03-19 | 2022-11-29 | XWPharma Ltd. | Pharmacokinetics of combined release formulations of a γ-hydroxybutyric acid derivative |
EP4346788A2 (en) | 2021-06-03 | 2024-04-10 | Arcadia Medicine, Inc. | Enantiomeric entactogen compositions and methods of their use |
US11845736B2 (en) | 2021-10-01 | 2023-12-19 | Empathbio, Inc. | Prodrugs of MDMA, MDA, and derivatives thereof |
WO2023129958A2 (en) | 2021-12-28 | 2023-07-06 | ATAI Life Sciences AG | Nitric oxide releasing prodrugs of mda and mdma |
US11583510B1 (en) | 2022-02-07 | 2023-02-21 | Flamel Ireland Limited | Methods of administering gamma hydroxybutyrate formulations after a high-fat meal |
US11779557B1 (en) | 2022-02-07 | 2023-10-10 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6228863B1 (en) * | 1997-12-22 | 2001-05-08 | Euro-Celtique S.A. | Method of preventing abuse of opioid dosage forms |
US6309668B1 (en) * | 1994-02-01 | 2001-10-30 | Aventis Pharma Limited | Abuse resistant tablets |
-
2007
- 2007-09-12 WO PCT/US2007/019745 patent/WO2008033351A2/en active Application Filing
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6309668B1 (en) * | 1994-02-01 | 2001-10-30 | Aventis Pharma Limited | Abuse resistant tablets |
US6228863B1 (en) * | 1997-12-22 | 2001-05-08 | Euro-Celtique S.A. | Method of preventing abuse of opioid dosage forms |
Also Published As
Publication number | Publication date |
---|---|
WO2008033351A2 (en) | 2008-03-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2008033351A3 (en) | Multimodal abuse resistant and extended release formulations | |
WO2007087452A3 (en) | Abuse resistant and extended release formulations and method of use thereof | |
WO2008027442A3 (en) | Abuse deterrent oral pharmaceutical formulations of opioid agonists and method of use | |
AU2003280087A1 (en) | Dosage forms for increasing the solubility and extending the release of drugs such as e.g. topiramate and phenyton | |
WO2007146248A3 (en) | Stable laquinimod preparations | |
WO2008021394A3 (en) | Pharmaceutical formulations of cannabinoids and method of use | |
WO2008024490A3 (en) | Oral pharmaceutical formulations of abuse deterrent cannabinoids and method of use | |
ZA200901110B (en) | Pharmaceutically acceptable solubilizing composition and pharmaceutical dosage from containing same | |
IL196169A0 (en) | Bile acid derivatives and pharmaceutical compositions containing the same | |
WO2008024408A3 (en) | Pharmaceutical formulations of cannabinoids for application to the skin and method of use | |
WO2008066899A3 (en) | Nanoparticulate formulations and methods for the making and use thereof | |
EP1824442A4 (en) | Pharmaceutical and therapeutic compositions derived from garcinia mangostana l plant | |
ZA200809002B (en) | Cycloalkylamino acid derivatives and pharmaceutical compositions thereof | |
WO2008049116A3 (en) | Substituted indoles | |
IL229304A (en) | 1',3'-disubstituted- 4- phenyl- 3, 4, 5, 6 -tetrahydro-2h, 1'h - [1, 4'] bipyridinyl- 2'-ones, pharmaceutical compositions comprising them and uses thereof | |
AU2005339139A8 (en) | Pharmaceutical compositions and methods for treating or preventing oxalate-related disease | |
AP2008004671A0 (en) | Cycloalkylamino acid derivatives and pharmaceutical compositions thereof | |
EP1993519A4 (en) | Methods and compositions for deterring abuse of orally administered pharmaceutical products | |
WO2009081174A3 (en) | Anti - retroviral combination | |
WO2005117895A3 (en) | Compositions comprising meloxicam | |
WO2008006795A3 (en) | Indole compounds | |
IL189270A (en) | Phosphonated rifamycins and derivatives thereof, pharmaceutical compositions comprising the same and uses thereof in the preparation of medicaments for the prevention and treatment of bone and joint infections | |
WO2008129501A3 (en) | Pharmaceutical compositions of duloxetine | |
WO2008003050A3 (en) | Gallium nitrate formulations | |
WO2009068708A8 (en) | Pharmaceutical composition with prolonged release of somatostatin or an analogue thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 07838038 Country of ref document: EP Kind code of ref document: A2 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 07838038 Country of ref document: EP Kind code of ref document: A2 |